European Society for Medical Oncology Congress

MADRID — Nivolumab alone or in combination with ipilimumab as second- or third-line treatment demonstrated encouraging activity in patients…

MADRID — The addition of abemaciclib to endocrine therapy extended PFS and improved response rates among postmenopausal women with hormone…

MADRID — The addition of ramucirumab to docetaxel conferred a small but statistically significant PFS benefit for patients with advanced or…

MADRID — CT scan-based follow-up provided no significant survival benefit for patients who underwent complete resection for non-small cell lung…

MADRID — Adjuvant treatment with imatinib improved outcomes among patients with high-risk gastrointestinal stromal tumors, according to final…

MADRID — The addition of durvalumab to nab-paclitaxel slightly improved PFS and also improved response rates among patients with nonsquamous…

MADRID — The addition of pembrolizumab to pemetrexed and carboplatin for first-line therapy extended survival and improved response rates among…

MADRID — First-line osimertinib prolonged PFS by 54% compared with standard therapy among patients with EGFR-positive advanced non-small cell…

MADRID — Pembrolizumab demonstrated promising activity in patients with pretreated recurrent or metastatic gastric or gastroesophageal junction…

MADRID — The addition of abiraterone acetate plus prednisone to androgen deprivation therapy improved health-related quality of life among men…